MethylGene exercises royalty right in cancer drug collaboration with Celgene
By taking this action, MethylGene, after a 90-day transition period, will no longer be responsible for funding development costs required to obtain market approval for MGCD0103, and Celgene
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.